Abstract
A bioassay using dispersed pancreatic acini was used to measure fasting plasma cholecystokinin (CCK) concentrations in 105 patients with various kinds of gastrointestinal diseases, 17 patients with diabetes mellitus, and 6 healthy voluntters. High plasma CCK bioactivities were observed in patients with obstructive jaundice, choledocolithiasis, and primary biliary cirrhosis. Twenty-three samples with high CCK bioactivities were assayed by the same bioassay after the addition of a specific CCK antagonist and by a CCK radioimmunoassay in order to determine whether the high CCK-like bioactivity was due to circulating CCK or other factors. High CCK bioactivities were partially inhibited by the specific CCK antagonist, CR-1409, but the activities were not totally abolished. The residual bioactivities (not inhibited by CR-1409) correlated with plasma bile acid concentrations. The inhibitable CCK bioactivities correlated with plasma CCK levels obtained by radioimmunoassay. Although the bioassay using dispersed pancreatic acini has several advantages for measuring plasma CCK, this method overestimates CCK bioactivities in patients with high plasma bile acid concentrations.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Johnson LR: Regulation: Peptides of the gastrointestinal tract.In Gastrointestinal Physiology. LR Johnson (ed), St. Louis, CV Mosby, 1985, pp 1–13
Liddle RA, Goldfine ID, Williams JA: Bioassay of Plasma cholecystokinin in rats: Effects of food, trypsin inhibitor and alcohol. Gastroenterology 87:542–549, 1984
Nakamura R, Miyasaka K, Funakoshi A, Kitani K, Kuyama Y, Goseki K, Kino K, Tsuru M, Fukasawa T: Basal plasma cholecystokinin levels in digestive diseases—comparative study between CCK-8 like bioactivity by bioassay and CCK immunoreactivity by radioimmunoassay. Jpn J Gastroenterol 86:2572–2578, 1989 (Japanese, abstract in English)
Himeno S, Tarui S, Kanayama S, Hayashi C, Tateishi K, Imagawa K, Hashimura E, Hamaoka T, Kuroshima T, Shinomura Y: Plasma cholecystokinin responses after ingestion of liquid meal and intraduodenal infusion of fat, amino acids hydrochloric acid in man: Analysis with region specific radioimmunoassay. Am J Gastroenterol 78:703–707, 1983
Gores GJ, LaRusso NF, Miller LJ: Hepatic processing of cholecystokinnin peptids. I. Structural specificity and mechanism of hepatic extraction. Am J Physiol 250:344–349, 1986
Sakamoto T, Fujimura M, Newman J, Newman J, Zhu X-G, Greeley GH, Thompson JC: Comparison of hepatic elimination of different forms of cholecystokinin in dogs. J Clin Invest 75:280–285, 1985
Louie DS, May D, Miller P, Owyang C: Cholecystokinin mediates feedback regulation of pancreatic enzyme secretion in rats. Am J Physiol 250:252–259, 1986
Williams JA, Korc M, Dormer RL: Action of secretagogues on a new preparation of functionally intact, isolated pancreatic acini. Am J Physiol 235:3023–3029, 1978
Ceska M, Birath K, Brown B: A new and rapid method for the clinical determination of α-amylase activities in human serum and urine. Optimal conditions. Clin Chem Acta 26:437–444, 1969
Shinozaki H, Funakoshi A, Wakasugi H, Abe M: The inhibitory effect of CR-1409 on amylase secretion and intracellular Ca2+ mobilization in rat pancreatic acini in vitro. Jpn J Physiol 39:585–593, 1989
Funakoshi A, Nakano I, Shinozaki H, Tateishi K, Hamaoka T, Ibayashi H: High plasma cholecystokinin levels in patients with chronic pancreatitis having abdominal pain. Am J Gastroenterol 81:1174–1178, 1986
Kitani K, Kanai S: Tauroursodeoxycholate prevents taurocholate induced cholestasis. Life Sci 30:515–523, 1981
Okayama S, Kokubun N, Higashidate S, Uemura D, Hirata Y: High-performance liquid chromatographic separation of individual bile acids: free, glycine and taurine conjugated acids. Chem Lett 1443–1449, 1979
Chang TMS: Hemoperfusions over microencapsulated adsorbent in a patient with hepatic coma. Lancet 2:1371–1372, 1972
Eysselein VE, Reeve JR, Shievely JE, Hawke D, Walsh JH: Partial structure of a large canine cholecystokinin (CCK-58): amino acid sequence. Peptides 3:687–691, 1982
Dockray GJ: Immunochemical evidence of cholecystokininlike peptides in brain. Nature 264:568–570, 1976
Muller LJ, Straus E, Yalow RS: Cholecystokinin and its COOH-terminal octapeptide in the pig brain. Proc Natl Acad Sci USA 74:3035–3037, 1977
Rehfeld JF: Immunochemical studies on cholecystokinin. II. Distribution and molecular heterogeneity in the central nervous system and small intestine of man and hog. J Biol Chem 253:4016–4021 1978
Dockray GJ: Immunoreactive component resembling cholecystokinin octapeptide in intestine. Nature 270:359–361. 1977
Gomez G, Lluis F, Guo YS, Greeley GH, Townsend CM, Thompson JC: Bile inhibits release of cholecystokinin and neurotensin. Surgery 100:363–368, 1986
Nakamura R, Miyasaka K, Kuyama Y, Kitani K: Luminal bile regulates cholecystokinin release in conscious rats. Dig Dis Sci 35:55–60, 1990
Ohta H, Guan D, Tawil T, Liddle RA, Green GM: Regulation of plasma cholecystokinin levels by bile and bile acids in the rat. Gastroenterology 99:819–825, 1990
Takeyama Y, Nakanishi H, Ohyanagi H, Saitoh Y, Kaibuchi K, Takai Y: Enhancement of secretagogue-induced phosphoinositide turnover and amylase secretion by bile acids in isolated rat pancreatic acini. J Clin Invest 78:1604–1611, 1986
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Miyasaka, K., Funakoshi, A., Matsumoto, M. et al. Bile acids in human plasma interfere with cholecystokinin bioassay using dispersed pancreatic acini. Digest Dis Sci 36, 310–316 (1991). https://doi.org/10.1007/BF01318202
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01318202